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Dual Targeting of the Mesenchymal and Amoeboid Pathways: 
A Viable Therapy against Metastatic Breast Cancer 
 




Metastasis from the primary tumor site is the major cause of death in breast cancer, and 
acquisition of migration capacity is a key element for successful metastasis. Recently, it was 
found that expression of NEDD9, a focal adhesion associated scaffolding protein, could be used 
to switch between two types of single cell movement known as mesenchymal and amoeboid. 
Control of this “switch” can potentially open up new avenues of treatment against cancer 
metastasis. Simultaneous inhibition of both types of single cell movement may prevent cancer 
migration, thus decreasing cancer spreading and increasing survival of cancer patients. For 
example, forcibly pushing the switch toward amoeboid migration in combination with treatment 
against the kinase ROCK, a key component of amoeboid movement, might prove to be a vital 
strategy against metastasis. Currently, such strategies are not available in clinical practice. This 
project seeks to fill this gap in knowledge and provide new migration-based strategies to treat 
breast cancer metastases by 1) defining the impact of NEDD9 expression on regulation of 
mesenchymal invasion in breast cancer cells, 2) deciphering the mechanism and characterizing 
the key downstream effectors of NEDD9-dependent signaling that contribute to breast cancer 
mesenchymal migration, and 3) determining the anti-metastatic therapeutic benefit of inhibiting 
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CHAPTER 1: LITERATURE REVIEW 
 
I. Breast Cancer 
1.1: Importance of Breast Cancer Research 
Despite all advances in the field of breast cancer research, breast cancer remains the 
most commonly diagnosed cancer for women in the United States, as well as the second highest 
cause of cancer death in women behind lung cancer (1). It is estimated that 1 in 8 women 
(12.3%) in the United States will be diagnosed with breast cancer in their lifetime (2). This risk 
increases with age - the median age for women diagnosed with BC was 61 years old in 2015 
(2).  The American Cancer Society projects that in 2017 there will be over 250,000 newly 
diagnosed cases and over 40,000 new deaths as a result of invasive breast cancer (cancer.org). 
These startling statistics showcase a critical need for rapid advancements in therapeutic 
strategies against the invasive potential of this disease. 
 
1.2: Triple Negative Breast Cancer 
 The search for targetable biomarkers of breast cancer has yielded a few favorable targets 
with encouraging therapies. Around 60-70% of breast cancers have been found to have high 
expression of hormone receptors for estrogen or progesterone (3). Much success has been 
had against such cancers using hormone-targeting therapies like tamoxifen, which binds and 
inhibits estrogen receptor signaling, or aromatase inhibitors which suppress estrogen 
production (4, 5). Another 15% of breast cancers are positive for amplification of the oncogene 
HER2 (also referred to as HER2/neu or erbB2) (3). This gene codes for a receptor tyrosine 
kinase that complexes with other members of its family (EGFR/erbB1, erbB3, and erbB4) on 
the cell surface. Treatment against HER2-positive cancers has had much success using 
monoclonal antibody trastuzumab therapy (6, 7).  
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Breast cancers that are negative for expression of ER, PR, and HER2 are referred to as 
triple negative breast cancer (TNBC). TNBC comprises about 15-20% of all BC and is 
associated with increased tumor cell proliferation, substantial invasion and metastasis, and 
much poorer patient survival in comparison to other BCs (8, 9). TNBC is also associated with 
a higher incidence in mutation of the breast cancer tumor suppressor genes BRCA1 and 
BRCA2, which help maintain DNA integrity and control proper cell division/apoptosis (10, 11).  
The diminished survival rate of TNBC is not only due to the rampant aggressiveness of 
the disease, but also because of a decrease in the extent of applicable therapies. The lack of 
ER/PR/HER2 diminishes the number of available proven targeted treatment options, with 
cytotoxic chemotherapy being the main approved regimen (8). Circumstances of 
chemoresistance restrict potential remedies even further, unfortunately leaving very limited 
options. While breast cancer death rates have been on the decline in older women, they have 
remained fairly steady for women younger than 50 (cancer.org). This may be linked to TNBC 
being more commonly diagnosed in younger women (<50 years), who do not have as many 
treatment options as other BCs (8, 10). 
 
II. Metastasis and Types of Invasion 
2.1: Metastasis 
Metastasis of cancer cells from the primary tumor site is the most life-threatening aspect 
in the majority of diagnosed cancer cases. This involves a phenomenon known as epithelial-to-
mesenchymal transition or EMT, where normal epithelial cells lose their polarity and cell-cell 
adhesions to become invasive mesenchymal cells (12). These cells can then invade neighboring 
tissues or break through the basement membrane into the blood stream by intravasation and be 
carried to a distant site in the body for further colonization. Once cancerous cells are able to 
enter the blood stream, survival rate of the patient is likely to decrease at an accelerated rate. 
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Cancer cells are capable of migrating either collectively or individually (13-16). Individual 
invasive cells lose all cell-cell adhesions and are known to be able to invade via two different 
methods of migration known as mesenchymal and amoeboid (17-19). Depending upon 
conditions such as extracellular matrix (ECM) composition, pore size, and rigidity of the cell 
microenvironment, these two methods can be used interchangeably by the same cell population 
in order to invade into different areas (14, 18). For example, since the interstitial matrices of the 
human body are heterogeneous - ranging from loose fibrillary regions to dense connective tissue 
- macrophages have been shown to utilize both mesenchymal and amoeboid migration to 
navigate such environments and reach different tissue sites (20-22). The switching between 
these two modes is referred to as mesenchymal-to-amoeboid transition (MAT) and amoeboid-
to-mesenchymal transition (AMT). 
 
2.2: Overview of Mesenchymal Invasion 
Mesenchymal migration is characterized by an elongated cell phenotype and the 
construction of lamellipodia actin structures at the mobile leading edge of the cell (17). 
Fibroblasts are commonly associated with this type of cell movement (23). The lamellipodium at 
the leading edge beneath the membrane is a typically broad treadmilling branched-actin 
meshwork, and helps to propel the cell across the microenvironment (24). Cell-matrix adhesion 
interactions, consisting of integrins and signaling protein clusters at the membrane that act as 
hubs between the extracellular matrix outside and the actin cytoskeleton inside, are quite strong 
in mesenchymal movement (17). This allows the leading edge of the cell to reach out, get a firm 
“grip” with the focal adhesions, and then follow up by pulling in the cell rear (23). In addition to 
this, mesenchymal movement is also characterized by the formation of invadopodia (25).  These 
long actin basal ventral membrane protrusions extend from the cell membrane for the purpose 
of matrix degradation. Through the activation of enzymes called matrix metalloproteinases or 
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MMPs at invadopodia membrane sites, the cell can cut holes through the ECM in order to clear 
a viable path for cell movement (17, 23). This ability to degrade matrix makes mesenchymal 
movement less restricted by the pore size of any given substratum, even allowing it to dig into 
bones (26). 
MMPs are especially useful for invasion of the basement membrane (BM), which is a 
dense matrix that lines the epithelium and endothelium layers and can act as a physical barrier 
to metastatic cells invading and entering the circulatory system. A dense reconstituted protein 
mixture that is prepared from mouse sarcoma is often used to experimentally test the ability of 
mesenchymal cells to invade basement membrane. This protein mixture, most commonly 
marketed under the name Matrigel, contains many ECM proteins including laminin, collagen IV, 
entactin, fibronectin, and vitronectin, thus making it a good representation of BM (27). The 
density and rigidity of this matrix makes mesenchymal movement ideal for invasion in such 
applications.  
 
2.3: Overview of Amoeboid Invasion 
Amoeboid migration is characterized by a more rounded cell phenotype and the 
contractility of cortical actomyosin fibers (17, 28). These tense contractile forces aid in the 
movement of the cell across matrices and can also result in representative blebbing of the cell 
membrane. This method of movement does not usually utilize matrix metalloproteinases, and 
instead deforms cell shape to squeeze through preexisting gaps or uses its contractile forces to 
slightly widen holes in the ECM (29). Due to its lack of use of MMPs, amoeboid movement is 
restricted in tissue with rigid highly crosslinked matrices like BM or bone, instead being most 
suited for invasion through less dense and more flexible microenvironments such as collagen I 
(20). Collagen I is the most abundant protein in human connective tissue and breast 
microenvironment, making it an excellent physiological representation of tumor 
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microenvironment when used in experimental studies (30). Common cells to use this type of 
movement are leukocytes such as neutrophils or monocytes, which do not require MMP 
enzymes to freely navigate through the flowing blood stream (23). 
Another point of difference is that cell-matrix adhesion interactions are diffuse and thus 
overall weaker in amoeboid cells in comparison to mesenchymal cells (17). This may provide 
an explanation for why amoeboid movement has been shown to be faster than mesenchymal in 
some reports, as the cells could quickly rearrange focal adhesions while rolling through existing 
holes in the ECM. The speed at which amoeboid cells can move is heavily linked to their 
microenvironment and the pore size of the extracellular matrix. The smaller the pore, the more 
difficult it is for the cell to deform its shape and squeeze through. The greatest limiting factor for 
the cell is the deformation of its nucleus, which must deform enough to squeeze through tight 
spaces but also be resilient enough to not rupture (28, 31). Complete arrest of amoeboid cell 
migration has been shown to occur when the pore size reaches about 10% of the nuclear cross 
section – for tumor cells, this is typically about 7µm2 (28). Nuclear lamin concentrations have 
been shown to play a large role in nuclear deformability regulation during amoeboid movement 
(31). Lamin proteins make up the main structural component of the nucleus, where they line the 
inside of the nuclear membrane to provide mechanical stability and scaffolding functions for 
protein and chromatin binding (32). Loss of lamin has no effect on migration ability through large 
pores, but severely hinders invasion through small pores due to compromise of the nuclear 
envelope. Likewise, too high of a lamin concentration makes it more difficult for the nucleus to 
deform, which can also hinder amoeboid invasion.  
 
2.4: Collective Invasion 
In collective migration, cells actually retain much of their epithelial characteristics such as 
cell-cell adhesions and invade in bonded layers. The cells at the leading edge of the sheet 
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typically have mesenchymal and proteolytic characteristics that allow for degradation of the 
matrix and pulling along of the sheet. Common physiological uses for this type of cell migration 
in the body are in embryonic development and wound healing.  This type of invasion is prominent 
in melanoma, large cell lung cancer, epithelial prostate cancer, and most commonly in 
squamous cell carcinoma (33). 
 
III. Molecular Machinery of Mesenchymal and Amoeboid Invasion 
3.1: The Rho Family of GTPases 
 The Rho family of GTPases, which is a subfamily of the Ras superfamily, is a class of 
small signaling G proteins (~21 kDa) known to heavily regulate intracellular actin dynamics and 
have roles in multiple functions including cell motility, cytoskeletal management, wound healing, 
cytokinesis, and organelle development (23). In mammals, over 20 members of this family have 
been identified, but the most common and extensively characterized are Rac1, RhoA, and cdc42 
(34). These proteins have been found to affect formation of lamellipodia/membrane ruffling, 
stress fibers, and filopodia, respectively (23). 
GTPases act as signaling switches by first binding guanosine triphosphate (GTP) and 
then binding various downstream effectors (24). To deactivate the signal, GTP is hydrolyzed by 
the protein into guanosine diphosphate (GDP), and the GTPase dissociates from the effector. 
These GTP- and GDP-bound states of GTPases are regulated by two different protein families: 
guanine nucleotide exchange factors (GEFs) which prime GTPases through facilitating the 
switching out of GDP for GTP, and GTPase-activating proteins (GAPs) which turn off GTPases 
through stimulation of their GTPase enzyme activity and subsequent hydrolysis of GTP to GDP 
(34).  
The mesenchymal and amoeboid pathways exhibit a competing relationship between the 
activities of Rac1 and RhoA GTPases (35, 36). Mesenchymal phenotype has been classified as 
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having high activity of Rac1, while amoeboid phenotype has high activity of RhoA (36). Both 
Rac1 and RhoA have their own subfamilies within the greater Rho family of GTPases, but Rac1 
and RhoA have been identified as the most important and main contributors to the 
mesenchymal/amoeboid motilities. The Rac-related subfamily includes Rac1, Rac2, and Rac3, 
which all share 80% sequence identity (23). While Rac1 is ubiquitously expressed throughout 
the body, Rac2 is only expressed in hematopoietic cells, where it has a role in NADPH oxidase 
activation and formation of reactive oxygen species (ROS) (23). Rac3 is expressed highly in 
brain, where it is thought to have a role in neuronal differentiation (37). The Rho-related 
subfamily, sharing 85% identity, consists of RhoA, RhoB, and RhoC (23, 38). All 3 members 
have been found to be ubiquitously expressed, but their subcellular localization varies (34). 
RhoA and RhoC localize to the plasma membrane, while RhoB localizes to endosomal 
membranes (39). This is thought to be due to their differences in 15 amino acids at the C-
terminal, where they exhibit the highest contrast (23, 34). RhoA and RhoC are both activated at 
the cell edge, playing roles in actomyosin contractility and cell movement (23). RhoC has also 
been implicated in promoting directional polarized migration, and appears to become activated 
slightly before RhoA (39, 40)  In contrast, the localization of RhoB to endosomes has shown it 
to have a role in intracellular trafficking, receptor-mediated angiogenesis, and cell survival (41).  
 
3.2: Proteins of the Mesenchymal Pathway 
Rac1 GTPase has been proven vital to the function of the mesenchymal pathway. Rac1 
binds and activates the WAVE regulatory complex (Wiskott-Aldrich syndrome protein family 
verprolin-homologous protein) (42). This activation by Rac1 causes a conformational change 
that releases inhibition on the VCA (verprolin, cofilin, acidic) domain of WASP family proteins 
like WAVE, allowing their VCA domain to bind and stabilize a small protein called Arp2/3 (actin-
related protein 2/3). Arp2/3, which physically resembles a cluster of monomeric globular actin, 
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acts as a seed for the polymerization of new actin filaments (42). This polymerization aids in the 
formation of actin-rich lamellipodia and invadopodia structures. Lamellipodia are broad sheet-
like membrane protrusions at the leading edge of the cell membrane, given structure by a dense 
and dynamic network of actin filaments, which assist in cell motility and mechanosensing of 
ECM rigidity (43). Invadopodia are more specialized actin-based protrusion structures – 
necessary for the degradation of ECM components and the basement membrane, subsequently 
promoting invasion and metastasis (44). 
Invadopodia formation localizes the activation and secretion of matrix metalloproteinases 
(MMPs), which are very important for the mesenchymal phenotype. This family of zinc-
dependent proteolytic enzymes modify and degrade components of the ECM to create tunnels 
and pathways for cells to invade (45, 46). The cleavage of ECM proteins by MMPs can also 
contribute to invasion through the uncovering and release of new binding sites in the ECM that 
can stimulate multiple signaling pathways such as proliferation, migration, or angiogenesis (47, 
48). In addition to their path-clearing capacity, MMPs can also dissociate cell-ECM and cell-cell 
junction connections, leading to the release of individual cells from epithelial sheets and 
promoting invasion (46, 49, 50).  Over 20 members of the MMP family exist in humans, which 
can be further classified into subgroups based on their main substrates or their structure. These 
include collagenases (MMP-1, MMP-8, MMP-13, MMP-18), which cleave collagens, gelatinases 
(MMP-2, MMP-9), which degrade gelatin/denatured collagens, stromelysins (MMP-3, MMP-10, 
MMP-11) and matrilysins (MMP-7), which target a wide variety of other non-collagen ECM 
proteins, and membrane-type MMPs (MT1-MMP/MMP-14, MMP-15, MMP-16, MMP-17, MMP-
24, MMP-25), which are transmembrane MMPs that express on the cell surface instead of being 
secreted (45, 46). Multiple specific MMPs have been found to have important roles and influence 
in the progression of breast cancer. For example, MMP-3 and MMP-7 both target E-cadherin, a 
transmembrane protein important for cell-cell junctions, causing disruption of cell aggregation, 
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releasing an active cleaved signaling molecule that stimulates invasion itself, and promoting 
EMT in mammary epithelial cells (51, 52). Furthermore, targeting of proteins such as protease 
activated receptor 1 (PAR-1) and P-cadherin by MMP-1 or MMP-2 has been shown to enhance 
invasion of breast cancer cells (53, 54). Additionally, the membrane-bound MT1-MMP has been 
linked to breast cancer invasion, seemingly through its processing of alpha-V integrin (55, 56). 
The importance of this link between MMP activity and the mesenchymal phenotype cannot be 
understated. 
 In order for Rac1 to carry out its role in regulating lamellipodia and invadopodia formation 
and subsequent MMP activation, it must first be activated itself by a GEF protein. Multiple GEFs 
for Rac1 GTPase such as VAV2, DOCK180, DEF6, ECT2, and DOCK8 have been identified in 
various tissues (57-61). In melanoma cell lines, it has been shown that Rac1 is activated by the 
Rac1 GEF DOCK3 (dedicator of cytokinesis 3), which is recruited to cell membranes through 
interaction with a scaffold protein called NEDD9 (neural precursor cell expressed 
developmentally down-regulated 9), also commonly referred to as Cas-L or HEF1 (human 
enhancer of filamentation 1) (35, 36). NEDD9 is a member of the Crk-associated substrate (Cas) 
family of proteins, which also includes p130cas/BCAR1, EfS/Sin1, and CASS4/HEPL (62). 
NEDD9 is known to participate in migration and proliferation pathways (12, 25, 63) and is 
commonly overexpressed in many human cancers, including both melanoma (64) and breast 
(12). Scaffold proteins like NEDD9 do not possess enzymatic activity of their own, but instead 
act as binding partners to bring multiple proteins together in a complex. It was shown in 
melanoma that large focal adhesion signaling complexes form in mesenchymal cells consisting 
of multiple proteins including integrin β3, Src, FAK (focal adhesion kinase), NEDD9, and DOCK3 
(35). These focal adhesion complexes act as signaling hubs mediating mechanical crosstalk 
between the extracellular matrix and the inside of the cell. Mesenchymal cells are known to 
possess larger, more mature focal adhesions which recruit multiple adaptor proteins such as 
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talin, paxillin, and vinculin. FA maturation leads to increased activation/phosphorylation of FAK 
and paxillin, and can occasionally culminate in the formation of very long fibrillary adhesions 
(65).  
Other proteins have been linked to the success of mesenchymal movement as well. 
Vascular endothelial growth factor (VEGF), a signaling protein which regulates vasculogenesis 
and angiogenesis, has been found to play a role in tumor growth and metastasis (66). 
Expression of the VEGF189 isoform, which binds at the cell membrane and interacts with the 
ECM, promotes mesenchymal phenotype and invasion (67).  Secretion of the soluble isoform 
VEGF165 has been linked to amoeboid phenotype and has been found to support blood stream 
extravasation and metastasis to a greater degree than VEGF189 (67, 68). Activity of VEGF189 
is enhanced through cleavage by proteases such as MMPs and urokinase plasminogen activator 
(69). Subsequently, expression of the urokinase plasminogen activator receptor (uPAR) has 
also been implicated in supporting mesenchymal invasion (70).  
Additionally, the cyclin-dependent kinase inhibitor 1B (p27Kip1) has been found to support 
mesenchymal motility and suppression of amoeboid signaling in multiple cells including 
macrophages (21), breast cancer (71), hepatocellular carcinoma (72), and melanoma (73). This 
role is dependent upon the transfer of p27 from the nucleus to the cytoplasm, where it co-
localizes with F-actin to help mediate Rac-driven migration (71-73). The exact substrates and 
mechanism by which p27 promotes Rac activation are not fully understood, however it has been 
shown that the C-terminal of p27 can bind RhoA and inhibit its activation through physical 
blockage of Rho-GEF interactions (74). This is an important example of how these pathways 
can exhibit control upon each other in order to downregulate the opposite pathway – this will be 




3.3: NEDD9 Promotes Mesenchymal Movement through an Additional AURKA-Driven 
Signaling Pathway 
It has been previously shown that NEDD9 contributes to activation and stabilization of 
the enzyme AURKA (75, 76), a serine/threonine kinase that is also overexpressed in a majority 
of human cancers including melanoma and breast (77-80). AURKA has been shown to 
phosphorylate the consensus sequence [R/K/N]-R-X-[S/T]-B, where B represents a hydrophobic 
amino acid (81). It is known that AURKA has a role in cell cycle and mitosis as a crucial enzyme 
in the formation of the mitotic spindle at the centrosome, linking it to cell proliferation processes 
(82). The common overexpression of this kinase in breast cancer correlates with poor survival 
in breast cancer patients (83). Nevertheless, the mechanisms of AURKA action on different 
stages of metastasis and particularly on invasion are currently unknown. 
AURKA has been previously shown to phosphorylate and activate the histone 
deacetylase HDAC6 (76). This activation of HDAC6 leads to deacetylation and increased activity 
of cortactin, an actin-binding scaffolding protein that contributes to actin branching and 
polymerization (84). Cortactin binds and stimulates Arp2/3 with its N-terminal region while 
simultaneously binding the sides of filamentous actin with its actin-binding repeat region (42). 
Interaction of Arp2/3 with Wiscott-Aldrich syndrome proteins like WASP or WAVE, which bind 
the SH3 domain of cortactin, can bring further stimulation to the activity and stability of Arp2/3 
(85). Additionally, Arpc1b, a component of Arp2/3, has been recently reported to be a direct 
substrate of AURKA, which may also help to trigger its activity (86). Once Arp2/3 is active, 
polymerization of branched actin from the sides of filaments can be formed, constructing a 
branched actin meshwork. This polymerization of monomeric actin as a result of cortactin, 
Arp2/3, and WASP family members is vital to the formation of lamellipodia and invadopodia 
structures in promoting mesenchymal movement.  
These additional signaling relationships as a result of NEDD9 expression suggest that in 
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addition to its role in activating the Rac1 signaling cascade, NEDD9 can also promote 
mesenchymal motility through a second cascade of interactions involving NEDD9, AURKA, and 
CTTN - potentially making NEDD9 a critical hub of invasive stimulation that may mark it as a 
prime therapeutic target. 
 
3.4: Proteins of the Amoeboid Pathway 
Similar to Rac1’s role in driving mesenchymal movement, the GTPase RhoA acts in a 
comparative manner to support the amoeboid signaling cascade. Multiple GEF proteins such as 
p114RhoGEF or Net1 have been found to activate RhoA (87-90). In breast cancer cells, it was 
shown that the cytokine CXCL12 helps support RhoA activation through its receptor CXCR4 and 
the GEF Net1 (90). Once active, RhoA binds and stimulates the Rho kinase ROCK (rho-
associated, coiled-coil containing protein kinase) (91). ROCK belongs to the AGC family of 
serine-threonine kinases and mainly functions in regulation of cytoskeletal proteins (92, 93). 
Amino acid consensus sequences for ROCK-targeted phosphorylation are [R/K]-X-[S/T] and 
[R/K]-X-X-[S/T], where the X amino acids can vary (94). The main target of ROCK in driving 
amoeboid migration is phosphorylation of MLC (myosin II light chain), thereby increasing 
actomyosin contractility of the cell membrane (92). ROCK can also phosphorylate and activate 
LIMK1, another protein kinase that functions to inactivate cofilin, an actin severing and 
depolymerization factor (95). LIMK1 was found to be critical for MAT in fibrosarcoma cells (96). 
Additional targets of RhoA include the formin Dia2 – interaction and colocalization between Dia2 
and its partner DIP (diaphanous interacting protein) have been found to be necessary for the 
formation of membrane blebbing areas in breast cancer cells, supporting amoeboid migration 
(90, 97). Another formin-related protein, FMNL2, has also been found to support amoeboid 
movement in breast cancer cells, however interestingly is more specific for RhoC GTPase 
interaction than RhoA (98). RhoC has also been shown to interact with FMNL3 (39). 
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In contrast to mesenchymal cells, amoeboid cells possess less mature focal adhesions 
and instead have many smaller, weaker nascent adhesions. These adhesions contain some of 
the same adaptor proteins as mature focal adhesions such as talin and paxillin, however the 
activation/phosphorylation of paxillin is decreased. Vinculin, a more mature FA marker, is less 
present in nascent adhesions. Loss of ERalpha, one of the hallmarks of TNBC, has been 
associated with a decrease in vinculin expression and an increase in amoeboid invasion and 
breast cancer metastasis (99). 
The protein ezrin, a crosslinker between the plasma membrane and the actin 
cytoskeleton, has been hypothesized to have an important role in focusing the directionality of 
amoeboid movement. In amoeboid-moving melanoma cells, ezrin was found to localize to the 
cell rear, where it tightly binds the plasma membrane and seems to locally hinder bleb formation 
(100). This model suggests that a tiny hydrostatic pressure released by bleb formations in the 
front of the cell is able to create a small polarized motile force, thus pulling the cell forward in 
the direction of bleb growth. 
Several other proteins have been implicated in supporting the amoeboid pathway or MAT 
in different cancer cell lines. In melanoma, TGF-beta stimulation was found to promote 
amoeboid phenotype along with increased expression of associated signaling transducers 
SMAD2, SMAD3, and CITED1 (101). Hypoxic conditions and expression of HIF-1alpha have 
been found to transition the collective movement of breast carcinoma and head and neck 
squamous cell carcinoma (HNSCC) cells to amoeboid migration (102). Other proteins whose 
expression has been reported to strengthen amoeboid phenotype include PKC-alpha (103), 
ACTN4 (104), EphA2 receptor tyrosine kinase (105), CD99 (106), NG2 (107), annexin II (108), 
transcription factors NANOG and Oct-4 (109), and collagen receptor Endo180 (110). The exact 




3.5: Regulation between Mesenchymal and Amoeboid Pathways 
To balance the competing relationship between mesenchymal and amoeboid 
phenotypes, various regulators have been shown to be utilized by each pathway to inhibit the 
competing signaling processes (35, 36). Upregulation of the microRNA let-7i by the amoeboid 
pathway has been shown to disrupt Rac1 signaling through suppressing expression of the 
mesenchymal proteins NEDD9 and DOCK3 in HNSCC cell lines (111, 112). Let-7i has also been 
found to repress expression of AURKA (113). As a counter, the transcriptional regulator Twist1, 
a known EMT inducer, has been shown to suppress expression of let-7i through the oncogene 
BMI1 (111-113).  Another microRNA, miR-200c, has also been found to be upregulated by 
amoeboid signaling. Increased ratio of miR-200c to its other miR-200 family member miR-200a 
was found to induce MAT through inhibition of expression of cytoskeletal regulatory proteins 
MARCKS, FHOD1, and PPM1F in melanoma and breast cancer cells (114, 115). Besides 
microRNA, the amoeboid pathway is also capable of disrupting Rac1 signaling through inhibition 
of p27Kip1 expression via ROCK-dependent stimulation of the ERK pathway (116, 117). In 
addition, the amoeboid pathway can upregulate Rac1 GAP proteins such as ARHGAP22 in 
melanoma (36) or FilGAP in multiple cancers to hinder Rac1 activity (118-120). Similarly, the 
mesenchymal pathway can upregulate RhoA GAPs such as RASAL2 in astrocytomas to 
downregulate RhoA activity (121). 
In melanoma, the mesenchymal pathway has been found to counter the amoeboid 
pathway through activation of Src by NEDD9, which phosphorylates and inhibits ROCK activity 
(35), and also through WAVE expression, although this exact mechanism is less well defined. It 
is hypothesized that an interactor of WAVE, Hem-1 (hematopoietic protein 1), may potentially 
interact with Rho GAPs or myosin phosphatase (36). Myosin phosphatase negatively controls 
amoeboid movement through dephosphorylation of MLC, and is known to be regulated through 
15  
direct phosphorylation by ROCK itself and also through Wnt signaling pathways (94, 122).  Wnt 
signaling proteins such as WNT5A are known activators of the RhoA/ROCK cascade and have 
been found to influence the amoeboid pathway (123, 124). In hepatocarcinoma cells, MMP 
inducer CD147 has been found to support the mesenchymal pathway through binding and 
inhibition of phosphorylation of annexin II, a phospholipid binding protein that is upregulated in 
amoeboid phenotype (61, 108). Together, this data illustrates the intense checks and balances 
that the mesenchymal and amoeboid pathways can enforce on each other to keep the opposite 
signaling networks suppressed.  
 
IV. Treatment of Breast Cancer Invasion and Metastasis 
4.1: Targeting the Mesenchymal Pathway 
Matrix metalloproteinases are an attractive target for stoppage of mesenchymal 
movement. Without these matrix degrading enzymes, tumor cells will encounter difficulty in 
being able to create tunnels and invade through the ECM. Whether through techniques such 
as siRNA knockdown or usage of MMP-targeting chemical compounds or small molecules, 
MMP inhibitors (MMPI) are a commonly used technique for targeting of cell invasion. Numerous 
MMPI which target many MMP proteins (broad spectrum) or a specific MMP protein have been 
designed and utilized over the years with varying degrees of success (125). Some MMPI have 
made it to clinical trials such as batimastat (phase I/II) (126-128) and marimastat (phase III) 
(129), but have not gained further traction due to different issues such as bioavailability, toxicity, 
or minimal effects on survival (130, 131). The only MMPI currently approved by the Food and 
Drug Administration is doxycycline, which is used as a treatment for periodontal disease (132). 
The difference in success between why some tumors respond to MMPIs better than others may 
be due to the potential of mixed cancer cell populations of both mesenchymal and amoeboid 
phenotypes and some populations leaning more heavily toward amoeboid, where MMP 
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inhibitors would have less effect. Nevertheless, inhibition of MMPs in in vitro or in vivo animal 
models has been shown to decrease Rac1 activity/cell elongation, increase RhoA activity/cell 
roundedness, and subsequently decrease cell invasion (70, 88, 105). This has been combined 
with targeting of uPAR in prostate and melanoma cancer cells, yielding exacerbated effects 
(70). 
Multiple other proteins have been targeted for inhibition of the mesenchymal pathway. 
Depletion of NEDD9 has been associated with a decrease in overall invasion and metastasis, 
as well as switching cells to a more amoeboid phenotype (133). This also has been shown to 
hinder the activation and secretion of MMPs (134, 135). Administration of the AURKA inhibitor 
MLN8237 (alisertib) decreases tumor growth and metastasis of breast cancer (136).  
An alternative option to “inhibit” the mesenchymal pathway could be to promote activation 
of the amoeboid pathway, thereby downregulating mesenchymal signaling. Use of calpeptin, a 
RhoA activator, has been used to switch mesenchymal melanoma cells to amoeboid migration, 
but with minimal effect on invasion (105).  
 
4.2: Targeting the Amoeboid Pathway 
Due to its vital role in regulation of actomyosin contractility and cytoskeletal 
rearrangement, the Rho kinase ROCK has become a popular drug target of the amoeboid 
pathway. Several ROCK inhibitor compounds have been designed – some of the earliest and 
most commonly tested being Y-27632 (137) and H-1152 (138). No ROCK inhibitors have yet 
been approved for human use in the United States by the Food and Drug Administration, 
however the compound fasudil has been permitted for clinical treatment of cerebral 
vasospasm in Japan and China (139, 140). Additionally, a derivative of fasudil called ripasudil 
has recently been approved for treatment of glaucoma in Japan (141). Despite no ROCK 
inhibitors being clinically available for treatment of human cancer, they have still shown 
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promise against blocking invasion and metastasis of cancer cell lines in vitro and in animal 
models (92). A newly developed compound, AT13148, which blocks multiple AGC kinases 
including ROCK, has shown substantial benefit against melanoma metastasis in mice (142). 
A phase I clinical trial for the inhibitor AT13148 is currently ongoing for evaluation against 
multiple cancer types with results expected to conclude this year (ClinicalTrials.gov identifier 
NCT01585701) (140). 
Knockdown or inhibition of various amoeboid pathway components besides ROCK have 
yielded promising results in hindering cell invasion and metastasis. The RhoA GEF 
p114RhoGEF was targeted in MDA-MB-231 TNBC cells and caused a decrease in migration, 
a decrease in RhoA activity, and an increase in Rac1 activity (87). Targeting of other RhoA 
GEFs such as Net1 has yielded similar results with decreases in BC cell migration and 
increases in elongated mesenchymal phenotype/MMP activity (89). PKCalpha inhibition 
switched melanoma and BC cells from rounded to elongated phenotype and decreased cell 
invasion, whereas activation of PKCalpha increased the percent of rounded cells, yet yielded 
no additional increase in invasion (103). ACTN4, a crosslinker of actin filaments at adherens 
junctions and focal adhesions, has been found to support rounded amoeboid morphology. 
Knockdown of ACTN4 decreased melanoma cell invasion, increased the persistence of FAs 
and switched cells to elongated phenotype (104). Additionally, chondramide, a naturally 
occurring compound that targets the actin cytoskeleton, has been shown to hinder amoeboid 
movement and breast cancer metastasis through inhibition of cell contractility (143). 
 
4.3: Dual Pathway Targeting 
Due to the fact that cancer cells have the ability to utilize both of these cell motility 
methods, the ideal treatment option may be one that hinders both pathways simultaneously. In 
doing so, the cell will not be able to invade even if it switches its phenotype to the opposite 
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pathway. This theory has been previously attempted in literature using combinations such as 
MMP and ROCK inhibitors in pancreatic and glioblastoma cancer cell lines (88, 144), Rac1 
siRNA with ROCK inhibitors in melanoma and glioblastoma cell lines (36, 145), and DOCK3 
siRNA or NEDD9 siRNA with ROCK inhibitors in melanoma cell lines (36), and MMP inhibitor 
and Rho GEF siRNA in breast cancer cell lines (87). Use of this dual targeting strategy showed 
a promising synergistic decrease in cell invasion upon concurrent suppression of mesenchymal 
and amoeboid processes. 
 
 
4.4: Comparisons of Mouse Models 
In order to assess the viability of such a treatment strategy for clinical trials, an in vivo 
mouse model offers a safe alternative to human patients and is a prevalent representation for 
the study of cancer. Multiple different types of models exist, including genetically-engineered 
mouse models (GEM), xenograft models (XG), and patient-derived xenograft models (PDX), all 
offering their own advantages and disadvantages (146). GEMs allow for the genome of a mouse 
population to be altered to either express, delete, or mutate some target gene of interest. NEDD9 
knockout animals have been previously made and are viable from birth (25). These models allow 
for the studying of tumor growth from the early stages of mouse development, but applicability 
of this knowledge is limited due to the growth of a murine tumor in a murine microenvironment, 
which may not correlate well with the development of human tumors. It is also a slow, time 
consuming, and expensive method.  
Xenograft models (XG) are cheaper and faster to do, and they allow for the growth of a 
human tumor in a mouse using human cancer cell lines.  However, this tumor of human cancer 
cells is still grown within a murine microenvironment, and in order for the tumor to propagate, 
the mouse host must lack a functional immune system, thus limiting our understanding of 
immune response to the tumor.  PDX models are similar to XG models in that they also have 
19  
similar concerns using a murine microenvironment and immune-compromised mice, however 
they differ by implantation of an actual piece of tumor tissue from a human patient into a mouse 
rather than utilization of immortalized cell lines. Unlike a cell line, this tumor tissue was originally 
grown in a human microenvironment and is a heterogeneous cell population, making this model 
one of the best systems to study human tumor growth, metastasis, and anti-cancer drug 
response. Disadvantages of PDX models include the scarcity and expensiveness of their source 
material, which must be isolated from human patient tumors, and the fact that they are less 
easily manipulated. Normal XG models do not have these issues, since cell lines are readily 
available and much simpler to engineer or alter for experimental procedures. 
 
V. Hypothesis 
It is currently unknown whether previous findings of NEDD9 having a pivotal role in the 
switch between mesenchymal/amoeboid migration processes in melanoma could be applied to 
other cancers, notably breast cancer (35, 36). The downstream targets of the NEDD9-dependent 
signaling pathway involved in regulation of mesenchymal migration in breast cancer are also 
currently unknown. The central hypothesis of this project was that simultaneous inhibition of key 
components of both the mesenchymal and amoeboid invasion pathways, including NEDD9 
protein expression, will have a synergistic effect limiting breast cancer migration and metastasis 
in vitro and in vivo.
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Commonly upregulated in human cancers, the scaffolding protein NEDD9/HEF1 is a known 
regulator of mesenchymal migration and cancer cell plasticity. However, the functional role of NEDD9 
as a regulator of different migration/invasion modes in the context of breast cancer metastasis is 
currently unknown. Here, it is reported that NEDD9 is necessary for both mesenchymal and amoeboid 
individual cell migration/invasion in triple-negative breast cancer (TNBC). NEDD9 deficiency results in 
acquisition of the amoeboid morphology, but severely limits all types of cell motility. Mechanistically, 
NEDD9 promotes mesenchymal migration via VAV2-dependent Rac1 activation, and depletion of 
VAV2 impairs the ability of NEDD9 to activate Rac1. Additionally, NEDD9 supports a mesenchymal 
phenotype through stimulating polymerization of actin via promoting CTTN phosphorylation in an 
AURKA-dependent manner. Interestingly, an increase in RhoA activity in NEDD9-depleted cells does 
not facilitate a switch to functional amoeboid motility, indicating a role of NEDD9 in the regulation of 
downstream RhoA signaling effectors. Simultaneous depletion of NEDD9 or inhibition of AURKA in 
combination with inhibition of the amoeboid driver ROCK results in an additional decrease in cancer 
cell migration/invasion. Finally, we confirmed that a dual targeting strategy is a viable and efficient 
therapeutic approach to hinder the metastasis of breast cancer in xenograft models, showcasing the 
important need for further clinical evaluation of this regimen in order to impede the spread of disease 
and improve patient survival. 
 
Implications: This study provides new insight into the therapeutic benefit of combining NEDD9 
depletion with ROCK inhibition to reduce tumor cell dissemination and discovers a new regulatory role 




Scaffolding protein NEDD9/HEF1, commonly overexpressed in many human cancers, is a 
critical regulator of cancer cell migration (1, 2). Cancer cells are capable of migrating either collectively 
or individually (3-5). In collective migration, cells retain most of their epithelial characteristics including 
cell-cell adhesions and invade as a sheet (6), thus enabling regional invasion and lymphatic-based 
metastasis. Alternatively, individual migration is distinguished by a loss of cell-cell adhesions and the 
ability to invade via two different methods known as mesenchymal and amoeboid (7-9), leading to 
blood-borne metastasis. Depending on extracellular matrix (ECM) composition and rigidity of the 
tumor microenvironment, the mesenchymal and amoeboid modes can be used interchangeably by 
the same cell population (3, 8). Initial nascent adhesions are highly present in amoeboid cells, 
consisting of integrin, talin, and non-phosphorylated paxillin. The recruitment of vinculin and FAK/Src 
complex and activation/phosphorylation of paxillin and FAK is indicative of focal adhesion (FA) 
maturation, which can culminate in formation of very elongated fibrillar adhesions (10), which are often 
found in mesenchymal cells. 
Elevated expression of NEDD9 protein is required for individual mesenchymal migration of 
diverse tumor cells (1, 11, 12). Mesenchymal migration is characterized by an elongated cell 
morphology, multiple focal/3D adhesions, and the ability to degrade ECM by matrix metalloproteinases 
(MMPs) (7, 13), creating a path through the basement membrane/tissue. A master regulator of 
mesenchymal migration, Rac1 GTPase, is activated by a number of guanine nucleotide exchange 
factors (GEFs), including melanoma-specific DOCK3 (14), which is recruited/activated by NEDD9 
(15). Rac1 activates the WAVE regulatory complex leading to polymerization of actin filaments (16). 
We have previously shown that NEDD9 also activates and stabilizes Aurora A kinase (AURKA) (17), 
which phosphorylates and activates histone deacetylase HDAC6 (18), leading to deacetylation and 
subsequent increased activity of the actin branching/stabilizing protein cortactin (CTTN) (19), which is 
necessary for lamellipodia and invadopodia formation - structures that define mesenchymal invasion. 
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Rac1-driven mesenchymal migration runs counter to the corresponding RhoA GTPase and 
ROCKII kinase-driven amoeboid pathway. Amoeboid migration is characterized by a rounder cell 
morphology, small/weak adhesions, and increased cell contractility (7, 20). This type of locomotion 
does not typically rely on matrix degradation, and instead slightly deforms the cell shape to squeeze 
through pre-existing gaps in the ECM (21). Because of this, amoeboid movement is more suited for 
invasion through less dense and more elastic matrices such as collagens. Mechanistically, RhoA binds 
and activates ROCKII which phosphorylates myosin II light chain (MLC2), thus increasing actomyosin 
contractility and amoeboid invasion. NEDD9 contributes to downregulation of the amoeboid pathway 
through binding/activating Src kinase, leading to phosphorylation/inhibition of ROCKII (11). 
The impact of NEDD9 on collective tumor cell invasion has not been explored. However, 
collective migration of lymphocytes in NEDD9 knockout mice was shown to be significantly reduced 
(22), and neuronal tube formation in mouse and chick embryos was inhibited upon NEDD9 depletion 
(23). We have shown that a decrease in NEDD9 expression leads to significant deficiency in activation 
of MMPs (24, 25), suggesting a deficiency of these cells to create tunnels through the matrix. 
Since individual tumor cells are capable of utilizing either one of these modes of movement, 
simultaneous targeting of both pathways may provide significant clinical benefit against metastatic 
cancers (14, 26). In this current study, we define the molecular mechanisms of NEDD9-dependent 
Rac1 activation and the efficacy of combined inhibition of both types of cell movement to hinder the 
metastasis of triple negative breast cancer (TNBC). 
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Materials and Methods 
Cell lines, RNAs, and plasmids 
TNBC cell lines MDA-MB-231LN (Caliper); Hs578T, HCC1143, BT549, HCC1395 (American 
Type Culture Collection); and SUM159 (gift from Dr. Boerner, Karmanos Cancer Institute) were 
authenticated and propagated for less than 6 months. si/sh/sgRNAs and plasmids used in this study 
are described in detail in the Supplementary Materials and Methods. The plasmids/RNAs were 
introduced via nucleofection (Amaxa) according to manufacturer’s recommendation or virus infection 
(293T packaging cells, LifeTechnologies) as previously described (24).  
Recombinant protein production 
Recombinant AURKA (19), wild type and N/C-term CTTN (27), and GST and GST-PBD 
proteins were produced  as previously described (28). 
Cell morphology analysis 
104 cells were plated on 2D or in 3D 1.5mg/ml collagen (Advanced BioMatrix) or 4mg/ml 
Matrigel (Corning) as previously described (30). Cells were treated with 50 or 100µM Y-27632 
(ApexBio) where indicated. Cells were brightfield imaged on a Leica DM/IL microscope. Cell 
elongation was measured as a function of cell length divided by cell width (ImageJ software/NIH). 
Western blotting 
Western blots were performed as previously described (24). Further details and a list of 
antibodies used can be found in the Supplemental Material and Methods. 
Immunofluorescence  
The edges of 18mm round glass coverslips (Fisher) were coated with a Super-HT-PAP-PEN 
hydrophobic slide marker and coated inside with 0.01% poly-L-lysine (Electron Microscopy Sciences). 
For 3D matrix embedding, 2.5x104 cells suspended in 200µl of 1.5mg/ml collagen-I or 4mg/ml Matrigel 
plug were loaded on the coverslips. Coverslips were placed into a 12-well plate and incubated in a 
37°C humid chamber during polymerization. Full media was added, and the cells were allowed to 
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acclimate to the matrix for 48 hours. Fixation and immunofluorescence staining was carried out as 
previously described (29). The list of used antibodies and quantification details are provided in the 
Supplemental Material and Methods. 
Collagen gel contraction assay 
 1x106 cells per sample were suspended in 1.5mg/ml collagen and inserted into a well in a 12-
well plate. Triplicate wells were included per cell line and a well with no cells was included as control. 
Once polymerized, media was placed on top of the collagen plug. After 24 hours, the collagen plugs 
were detached from the walls and bottom of the well. Gels were imaged (Syngene/G-Box) every 15 
minutes for the first few hours followed by hourly images up to 24 hours. Gel area was measured by 
manual outlining of the collagen plugs and analyzed in ImageJ. 
Radioactive kinase assays 
2.5μCi of [γ-32P]-ATP (Perkin Elmer) suspended in kinase buffer (28) was added to recombinant 
AURKA and/or CTTN (25-50ng) protein and incubated for 30 minutes at 30°C. Samples were then 
subjected to gel electrophoresis and membrane transfer followed by X-ray film exposure for 2 hours 
to visualize phosphorylation and western blotting to visualize total protein level. 
Actin polymerization assays 
Actin polymerization assays were carried out according to manufacturer’s recommendation 
(Cytoskeleton). Recombinant AURKA (3mM), CTTN (75nM), Arp2/3 (50nM, Cytoskeleton) or WASP-
VCA domain (5µM, Cytoskeleton) suspended in magnesium/ATP cocktail were added to 5µM pyrene-
labeled G-actin in a 96-well plate and actin polymerization was measured based on the increase of 
fluorescence at excitation 365nm/emission 407nm every 30 seconds for 20 minutes at 30°C using a 
GENios plate-reader (Tecan). 
Cell kymography 
 Kymography analysis was carried out as previously described (19). In brief, cells were plated 
on glass bottom dishes (Fisher Scientific) 48 hours after nucleofection with mCherry-LifeAct. Cells 
37  
were then treated overnight with 100nM AURKA inhibitor MLN8237 (Selleckchem) and live-imaged 
the next day every 45 seconds for 60 minutes. Kymograms were compiled from a perpendicular 1 
pixel-width line from each frame on the same spot of the cell membrane. 
Active Rac1 pulldown assays 
Cells were nucleofected with the indicated plasmids/siRNAs and allowed to recover overnight, 
followed by suspension of 1.5x105 cells in 450μl of 1.5mg/ml collagen-I or 4mg/ml Matrigel. In indicated 
assays, cells were also treated overnight with 4µM EHop-016 (ApexBio). After 24 hours, cells were 
lysed for 10 minutes on ice with 1X Rac1 lysis buffer as previously described (30). Lysates were spun 
down at max speed for 12 minutes at 4°C and supernatants were added to Glutathione-4FastFlow 
sepharose (GEHealthcare) loaded with GST or GST-PBD protein, rotating at 4°C for at least 1 hour. 
Sepharose was then washed three times with lysis buffer, boiled in Laemmli buffer and subjected to 
gel electrophoresis and western blotting. 
Active Rac1 and RhoA G-LISA assays 
 G-LISA activation assays for Rac1 and RhoA were performed as recommended by the 
manufacturer’s protocol (Cytoskeleton). 
Immunoprecipitations of GEF proteins 
pcDNA3.1-mRFP-NEDD9 and Rac1 GEF-expressing plasmids were co-transfected into 293T 
cells using TurboFect (ThermoFisher) per manufacturer protocol. After 24 hours, cells were lysed with 
PTY lysis buffer and processed as previously described (28). Lysates were precleared with protein-
A/G-sepharose (GEHealthcare) for 1 hour at 4°C. Mouse IgG control/or anti-NEDD9 (2G9) protein-
A/G sepharose, or anti-HA/anti-FLAG EZview-Red antibody (Sigma) were added to precleared lysates 
for 12 hours rotating at 4°C. Beads were then washed three times with PTY buffer. To elute proteins 
from the beads, 10% ammonia hydroxide was added for 15 seconds followed by speed-vacuum 
centrifuge to remove ammonia hydroxide. Protein was then resuspended in Laemmli buffer for gel 
electrophoresis and western blotting. The IP of CTTN is detailed in the Supplemental Materials and 
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Methods. 
Live-cell imaging of individual cell invasion  
Cells treated with si/sgRNAs against NEDD9 or RhoA and/or overexpressing CA-RhoA and/or 
treated with 50µM Y-27632 or 100nM MLN8237 for 24h were re-suspended in 1.5mg/ml collagen and 
placed into 3D-Chemotaxis µ-slides (Ibidi) according to manufacturer protocol. Fetal bovine serum 
was added to the left media reservoir to create a chemoattractant gradient. When used, Y-27632 
and/or MLN8237 were also added to both reservoirs to keep the drugs present during the assay. Cells 
were imaged every 15 minutes via DIC 10X objective on a Nikon Sweptfield/Eclipse/TE2000-E 
confocal microscope for 23 hours. Time lapse images were imported into ImageJ software and 
combined to form video files. Quantification methods are detailed in the Supplemental Materials and 
Methods.  
Live-cell imaging of collective cell invasion  
1x105 cells in full medium were plated on top of 4-5mg/ml Matrigel-coated delta-T dishes 
(Bioptechs). After 1 hour, the medium was removed and the cell layer was covered with more Matrigel. 
After polymerizing for 30 minutes at 37°C, media was re-added. Live-cell imaging was conducted 
every 10 minutes for 24 hours at 37°C via Nikon Sweptfield/Eclipse/TE2000-E confocal microscope 
(20X objective). Time lapse images were imported into ImageJ software and combined to form video 
files. Quantification methods are detailed in the Supplemental Materials and Methods. 
Fluorescent imaging of collective cell invasion sandwich assay  
Cells were pretreated overnight with 50µM Y-27632 or 100nM MLN8237, and 3x104 cells were 
plated in 8-well chamber slides (ThermoFisher) coated with 150µl 4mg/ml Matrigel. After 1 hour, the 
medium was removed and the cells covered with another 200µl Matrigel, followed by full media after 
Matrigel polymerization. Cells were live imaged in 5µm Z-steps away from the cell seeding position at 
72 hours using a Nikon Sweptfield/Eclipse/TE2000-E confocal microscope. Invasion was quantified 
by total cell fluorescence intensity at the furthest distance cells reached (100µm). 3D invasion boxes 
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were constructed using the Volume-Viewer plugin for ImageJ to show cell fluorescence signal 
throughout the Matrigel from the seeding position. 
Mouse xenograft study 
Animals were housed in the WVU Animal Facility under pathogen-free conditions according to 
an approved Institutional Animal Care and Use Committee protocol. 1x106 MDA-MB-231-luc2 cells 
expressing doxycycline-inducible pTRIPZ-RFP-shControl or shNEDD9 (25) were suspended in 
4mg/ml Matrigel (Trevigen) and injected into the mammary fat pad of 6-8-weeks old immunodeficient 
female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (Jackson Laboratory). Mice with mammary 
tumors (150-200mm3) were pre-treated in neoadjuvant settings with 10mg/kg AURKA inhibitor 
MLN8237 via oral gavage for 1 week (4 days on, 3 days off) as previously described to temporarily 
halt metastasis, but continue mammary tumor growth (31). shRNA expression in tumor cells was 
induced via introduction of doxycycline-containing food (Bio-Serv) in combination with vehicle or 
10mg/kg Y-27632 which was administered by oral gavage for 3 weeks (4 days on, 3 days off). Tumor 
growth and dissemination was evaluated weekly through in vivo whole-body bioluminescence imaging 
(BLI) using an IVIS/Lumina-II system as previously described (17). After 3 weeks, lungs, mammary 
tumors, and blood were collected for analysis. Paraffin-embedded lung sections were stained by 
hematoxylin and eosin (H&E) and analyzed for the number of metastases per lung area by a 
pathologist as previously described (17). Primary tumors were analyzed for NEDD9 expression by 
western blot. Ten mice per both shRNA groups (further separated into 5 per drug group for a total of 
20 mice) were used based on statistical analysis. 
Quantification of circulating tumor cells 
Submandibular mouse blood samples were collected into EDTA-coated tubes on ice to prevent 
clotting. Erythrocytes were lysed and removed from blood via incubation with RBC lysis buffer 
(eBioscience) according to manufacturer’s protocol. Cells were fixed in 2% paraformaldehyde for 10 
minutes, followed by centrifugation at 500g for 5 minutes at 4°C, and resuspended in 1% BSA/PBS. 
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Flow cytometry (FACS) was performed using a BD Biosciences/LSR Fortessa to count RFP-positive 
circulating tumor cells in the blood samples. Final counts were normalized to initial primary tumor size 
at week zero. 
Statistical analysis 
One-way ANOVA or student’s t-test statistical analyses were performed with GraphPad Prism 
software where noted. p ≤ 0.05 was considered to be significant (*). Experimental values were reported 




TNBC cell morphology changes upon NEDD9 and ROCK inhibition 
Metastatic TNBC cell lines with primarily mesenchymal morphology (MDA-MB-231, BT549, 
HCC1143, HCC1395, Hs578T and SUM159) were used to assess the role of NEDD9 in switching 
cells from mesenchymal to amoeboid morphology. NEDD9 was depleted using previously 
characterized siRNAs (17, 32) (Fig.1A) in a SMARTpool, and the changes in individual cell 
morphology were monitored using live cell imaging microscopy when plated in 2D or suspended in 3D 
matrix (collagen I or Matrigel).  
In 2D, control (siCon) cells have well-defined elongated morphology, while NEDD9-depleted 
(siNEDD9) cells show up to a 40% decrease in cell elongation (Fig.S1A-B) reflected by a decrease in 
the ratio of cell length over cell width. In 3D matrix, the pore size is a critical determinant of cell 
morphology and migration type (20). The average pore size of the collagen I matrix used was about 
15 µm2 (Fig.S1C-D), which supports both amoeboid and mesenchymal movement (33). Alternatively, 
the tightly-packed fibers that make up Matrigel are not conducive for amoeboid migration (<1 µm) and 
are permissive primarily for matrix-degrading mesenchymal movement. Interestingly, when seeded in 
either of these 3D scaffolds, siNEDD9 cells show acquisition of rounded amoeboid morphology and 
up to a 50% decrease in cell elongation (Fig.1B-C), which is similar to 2D results.  
Knockout of NEDD9 using sgRNAs and CRISPR/Cas9 technology led to similar changes in 
morphology with less variability in cell elongation and showing an elongation ratio closer to 1, 
indicating that they are more circular with similar cell length and width (Fig.S1E-F). This phenotype 
was similar to cells overexpressing constitutively active RhoA GTPase (Fig.1D-F), suggesting RhoA 
activity may be high in NEDD9 deficient cells. Importantly, almost all TNBC cells demonstrated 
significant plasticity in their ability to not only be able to switch to amoeboid morphology, but also be 
able to increase mesenchymal morphology, which was confirmed as control cells became further 
elongated upon application of the well-characterized Rho kinase inhibitor, Y-27632 (Fig.1G-H).  
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NEDD9 depletion leads to increased myosin light chain phosphorylation but decreased 
contractility 
Next, we tested if the acquisition of amoeboid morphology by NEDD9-deficient TNBC cells is 
accompanied by a switch to amoeboid migration, which could potentially promote intra/extravasation 
during metastasis of breast cancer. Actomyosin contractility and force-mediated remodeling of the 
matrix is a signature of the amoeboid type of cell migration (34). A key driver of actomyosin contractility 
is the Rho kinase ROCK, which phosphorylates myosin II light chain (MLC2) (35). In both collagen 
and Matrigel, NEDD9 deficiency resulted in up to a threefold increase in pMLC2 (Fig.2A-D, Fig.S1J), 
which co-localized with cortical actin around the cell membrane.  
Interestingly, despite this increase in pMLC2 in NEDD9-depleted cells, there was a significant 
decrease in the ability of the collective cell population to contract floating collagen gels (Fig.2E-F), 
indicating that morphologically amoeboid NEDD9-depleted cells may not possess all of the 
mechanistic properties of amoeboid cells. The inability of NEDD9-deficient cells to translate the 
increased pMLC2 signaling to matrix deformation/contraction may be indicative of impaired adhesion 
or actin dynamics connecting the internal and external forces of the cell. 
NEDD9 depletion leads to a decrease in mature focal adhesion dynamics 
Mature, large focal adhesions have been associated with the mesenchymal phenotype, 
whereas a decrease in size and maturity has been linked to amoeboid morphology (36, 37). Staining 
for phospho-FAK (pFAKY397) or phospho-paxillin (pPaxillinY31) has been commonly used to label 
mature focal adhesions (37, 38). Immunofluorescence analysis shows up to a twofold decrease in the 
number of adhesions positive for pFAKY397 and pPaxillinY31 upon NEDD9 depletion (Fig.2G-J, S1G-
J), indicating a critical role of NEDD9 in adhesion maturation. The decrease in FAK and paxillin 
phosphorylation was further confirmed by western blot in multiple breast cancer cell lines (Fig.2K-M, 
S2). NEDD9 deficiency trended toward a decrease in the number of adhesions containing the more 
mature/stable focal adhesion marker vinculin (39), which would be concurrent with amoeboid 
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phenotype, however the length of many of these adhesions was increased compared to control, 
suggesting the stabilization of fibrillar adhesions (Fig.S3). Nevertheless, NEDD9-depleted cells also 
had an increase in the total number of small adhesions that contained talin (Fig.S4), which is one of 
the first proteins recruited to focal contacts/adhesions (39). This indicates that there is an increase in 
small, weak nascent adhesions and a decrease in mature adhesions, which is concurrent with 
amoeboid phenotype (40). This may suggest that NEDD9 is not needed for adhesion initiation but is 
required for fibrillary adhesion disassembly. Such duality may potentially affect both mesenchymal 
and amoeboid adhesion dynamics. 
NEDD9 regulates AURKA-driven phosphorylation of CTTN and stability of actin filaments 
Amoeboid morphology is characterized by a decrease in filamentous actin polymerization while 
the mesenchymal elongated shape relies on an increase in filamentous actin (7). Previously, we have 
shown that NEDD9 binds and activates AURKA and the actin stabilizing protein CTTN, which results 
in an increase in actin polymerization and stabilization of lamellar protrusions and invadopodia (19). 
Here we show that AURKA directly phosphorylates CTTN (Fig.3A) at the (C-terminus 350-546aa) 
(Fig.3B, S5). To assess the impact of this phosphorylation on actin dynamics, an in vitro actin 
polymerization assay was carried out using recombinant AURKA and CTTN proteins. Incubation of 
AURKA with CTTN resulted in a significant increase in the actin polymerization rate (Fig.3C) 
compared to CTTN without AURKA. AURKA alone or in combination with Arp2/3 and WASP did not 
significantly affect actin polymerization, indicating that CTTN is the major substrate of AURKA in this 
assay. Moreover, kymography analysis of mCherry-LifeAct-expressing cells shows that the inhibition 
of AURKA results in a complete blockade of lamellar protrusions (Fig.3D-F), indicating that AURKA 
has a key role in cellular actin dynamics. 
NEDD9 depletion decreases Rac1 activity in breast cancer cells 
Rac1 GTPase has been shown to be one of the key drivers of mesenchymal 
migration/morphology. To measure Rac1 activity in cells grown in either 3D collagen or Matrigel, GST-
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tagged PBD (PAK p21 binding domain) protein was used to specifically pull down Rac1-GTP. Cells 
overexpressing dominant negative Rac1 (DN) or constitutively active Rac1 (CA) were used as controls 
(Fig.S6A). NEDD9 depletion resulted in a significant decrease in the amount of active Rac1 in cells 
grown in both scaffolds (Fig.4A-B). This was consistent when repeated in two other mesenchymal 
breast cancer cell lines as well, Hs578T and HCC1143 (Fig.S6B-C). As a complementary approach, 
Rac1 G-LISA assays (41) were used to evaluate the effect of NEDD9 depletion. Similarly to the active 
Rac1 pulldown assay, Rac1 G-LISA shows a decrease in the amount of active Rac1 (Fig.4B, 
Fig.S6D). Additionally, the RhoA G-LISA shows an increase in the amount of active RhoA, which is 
concurrent with amoeboid phenotype (Fig.4C).  
NEDD9 drives Rac1 activity through interaction with GEF VAV2 
Previously, it was shown in melanoma cells that NEDD9 activates Rac1 via interaction with the 
Rac1-GEF DOCK3 (15). Based on the breast cancer cell expression profiles of different GEFs and 
their downstream effectors, several potential Rac1 GEF candidates were examined for their ability to 
bind NEDD9 in co-immunoprecipitation experiments including DOCK4, DOCK180, VAV2, Tiam1, 
GEF-H1, ARHGEF2, ARHGEF4, DEF6, ECT2, and DBL (Supplementary Table 1). Some GEFs 
(such as DEF6, Fig.S6E) were co-immunoprecipitated with NEDD9 using anti-NEDD9 specific 
monoclonal (2G9) antibody, however only VAV2 was found to also reciprocally pull down NEDD9 
(Fig.4D, Fig.S6F) when immunoprecipitating VAV2. To confirm that VAV2 is required for Rac1 
activation in breast cancer cells, active Rac1 pulldowns were performed on cells treated with siCon or 
siRNA targeting VAV2 (Fig.4E). VAV2 depletion resulted in a 40-60% reduction in activity of Rac1 
(Fig.4F), supporting the notion that VAV2 is a critical downstream effector of NEDD9-dependent Rac1 
activation. Importantly, treatment of siCon cells with EHop-016 (42), a small molecular compound 
which inhibits Rac1 activation by VAV2 through interaction with Rac1’s VAV2-binding site, resulted in 
a reduction in Rac1 activity that was similar to the effect caused by siNEDD9 (Fig.S6G-H). This 
inhibition effect by EHop-016 was not found to be additive when combined with NEDD9 depletion. 
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Additionally, an increase in Rac1 activity through NEDD9 overexpression was able to be blocked by 
VAV2 knockdown, further supporting that NEDD9-induced Rac1 activity is VAV2 dependent (Fig.4G). 
Simultaneous targeting of NEDD9 and ROCK/RhoA hinders breast cancer cell motility/invasion 
in vitro 
Since NEDD9 depletion supports the ROCK/RhoA pathway, knockdown of NEDD9 was 
combined with the ROCK-targeting compound Y-27632 to test for an additional therapeutic benefit in 
3D invasion assays. NEDD9 depletion alone (via siRNA or sgRNA) led to an increase in amoeboid 
morphology and drastically decreased invasion (Fig.5A-E, Vid.S1; Fig.S7A-D, Vid.S2), similar to the 
overexpression of constitutively active RhoA (Fig.S7F-J, Vid.S3). Combination of Y-27632+siNEDD9 
led to an increase in leading edge speed (extension/retraction), but decreased the cell body speed, 
thus rendering the elongated cell immobile (Fig.5C). The directionality and elongation of Y-27632-
treated cells was significantly increased regardless of NEDD9 depletion (Fig.5D-E). As a 
complementary approach, RhoA depletion was performed and resulted in comparable trends (Fig.S8, 
Vid.S4). Effects on invasion were also evaluated using Hs578T and HCC1143 cells treated with 
siNEDD9, confirming similar results (Fig.S9, Vid.S5-6). Additionally, the AURKA inhibitor MLN8237 
was tested as a substitute for siNEDD9 in combination treatments. Cell invasion distance was found 
to be decreased with MLN8237/Y-27632 treatment, and was similar to the efficacy of siNEDD9/Y-
27632 treatment (Fig.S10A-B, Vid.S7). This suggests that MLN8237/Y-27632 could potentially be a 
viable combination regimen as well. 
NEDD9 is required for collective migration in 3D matrix 
To test the impact of NEDD9 depletion on collective tumor cell invasion, cells were seeded in 
high density while sandwiched in between two Matrigel layers and time lapse microscopy was 
performed. Control cells invaded as strand-like collective streams (“highways”), similar to previous 
observations (9) (Fig.5F, Vid.S8). Formation of these streams is diminished following NEDD9 
knockdown, which suggests the cells have minimal matrix degradation and/or rearrangement capacity. 
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This deficiency in path-generating activity is required for leading cells during collective invasion. 
Additionally, cell speed and directionality were both significantly decreased in NEDD9-depleted cells 
(Fig.5G-H), which corroborates with a significant reduction in their invasion distance (Fig.5I-K). 
Furthermore, inhibition of AURKA yielded a similar decrease in collective cell invasion compared to 
NEDD9 depletion (Fig.S10C-D), again suggesting that AURKA could be a viable therapeutic target. 
Combination of NEDD9 knockdown and Y-27632 treatment hinders breast cancer cell invasion 
and metastasis in vivo 
MDA-MB-231-luc2 pTRIPZ-RFP-shControl or shNEDD9 cells were injected into the mammary 
fat pad of NSG mice. After 2.5 weeks, mice were treated with the AURKA inhibitor MLN8237 (4 days 
on, 3 days off) to prevent pulmonary metastases outgrowth without any effect on the mammary tumor 
growth as we previously reported (17). 72 hours post-MLN8237 pretreatment, mice with tumors were 
subjected to doxycycline-induced shCon or shNEDD9 expression and administration of Y-27632 
compound for 3 weeks (Fig.6A). Primary tumor growth was measured weekly and was significantly 
reduced in shNEDD9/Y-27632 combination-treated animals compared to vehicle (Fig.6B-C). At the 
end of the study, NEDD9 depletion was confirmed in the mammary tumors by western blot (Fig.6D-
E). To measure the metastatic ability of the tumor cells, terminal blood samples were collected and 
analyzed after euthanization for circulating tumor cells (CTCs) using flow cytometry. Nearly a 40% 
reduction in the number of CTCs was documented with shNEDD9 induction, which decreased even 
further with addition of Y-27632 (Fig.6F). A significant abatement in the number of metastases per 
lung area was seen with NEDD9 knockdown, and an even more pronounced inhibition was seen in 
combination with Y-27632 (Fig.6G), supporting our hypothesis that dual targeting of both the 
mesenchymal and amoeboid pathways via NEDD9 and ROCK/RhoA can be a promising therapy 




NEDD9 protein is found consistently upregulated in TNBCs and highly correlates with 
invasive/metastatic spread (1, 17). Our findings provide a mechanistic explanation for NEDD9-driven 
invasion processes and strongly advocates for the combination of anti-NEDD9/AURKA and anti-
ROCK targeting compounds to inhibit these movement signaling cascades. In this study, we report 
that deficiency in NEDD9 signaling itself leads to inhibition of key aspects of both mesenchymal and 
amoeboid migration in TNBC cells, resulting in substantial hindrance on cell invasion and metastasis. 
Similar to results in melanoma (14), NEDD9 deficiency in TNBC cells results in rounded/amoeboid 
morphology along with a decrease in the total number of mature (pFAK/pPaxillin positive) adhesions 
and an increase in the number of nascent adhesions (40). However, these cells also saw an increase 
in long fibrillar adhesions (Fig.S3D). These findings suggest that NEDD9 is also required for the 
disassembly of fibrillar adhesions similar to vinculin (43), which regulates the recruitment and release 
of focal adhesion proteins in a force-dependent manner (44). The role of NEDD9/HEF1 as a sensor 
of altered adhesion states has been previously reported (45). A decrease in disassembly could be due 
to matrix metalloprotease inhibition (46), as previously reported by our group (24). Hindered 
disassembly of FAs would be in disagreement with a previously noted increase in adhesion turnover 
of NEDD9-KO or mutant NEDD9 (Y189A) expressing fibroblasts in 2D cultures (47, 48), however the 
structure, composition, and dynamics of adhesions in 2D fibroblasts may be different from 3D tumor 
cells.  
NEDD9 deficiency led to an increase in myosin-phosphorylated amoeboid-like cells, but this 
increase in pMLC2 did not translate to increased collective-cell contractility or invasion in 3D matrix. 
This disconnect may suggest a potential de-coupling between the actin filaments and myosin motors 
during cell body contraction (49). Alternatively, the inability of NEDD9-deficient cells to disassemble 
adhesions as we have suggested would limit amoeboid movement, which is in agreement with our 
previous reports on integrin dynamics (32). 
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Consistent with past findings, we found that NEDD9 deficiency resulted in over a 50% decrease 
in active Rac1, suggesting that NEDD9 is critical for Rac1 activation to occur in TNBC cells. We 
discovered that an interaction between NEDD9 and the Rac1-GEF protein VAV2 is required for Rac1 
activation. Similar to NEDD9 depletion, loss of VAV2 yields a comparable decrease in Rac1 activity. 
Furthermore, the small molecule compound EHop-016, which efficiently blocks the interaction of Rac1 
with VAV2 (42), did not cause an additive effect on Rac1 inhibition when given to siNEDD9 cells, 
suggesting that NEDD9 and VAV2 share the same pathway to Rac1 activation. The potential clinical 
application of this compound has yet to be determined, however another VAV-family targeting drug, 
the purine analogue azathioprine, was recently found to inhibit pancreatic cancer metastasis (50). 
Additionally, overexpression of NEDD9 increased Rac1 activity, which was abrogated upon depletion 
of VAV2, supporting that NEDD9’s influence on Rac1 activation is VAV2-dependent. Selecting NEDD9 
as a therapeutic target could potentially be more beneficial than targeting VAV2 due to its upstream 
placement in the mesenchymal pathway and the multiple downstream branches that it links to 
including VAV2/Rac1 and AURKA/CTTN. The effect of AURKA inhibition on actin dynamics in TNBCs 
and its ability to regulate filamentous actin polymerization via phosphorylation of CTTN suggests a 
potential mechanistic explanation for the mesenchymal to amoeboid morphology changes observed 
upon NEDD9 depletion and provides additional venues to explore CTTN/AURKA signaling in TNBC 
metastasis. 
In collagen invasion assays, both NEDD9-deficient and MLN8237-treated cells underwent a 
drastic reduction in cell invasion. It was anticipated that amoeboid cells could potentially move faster 
with a more erratic cell trajectory. While a small decrease in directionality was seen upon NEDD9 
depletion, it was not significant. Inhibition of ROCK or RhoA in NEDD9-deficient TNBC cells reverted 
them back to an elongated cell shape, but not their original migration proficiency. These combination-
treated cells also had a significant increase in cell directionality - this is likely due to their significant 
increase in cell length which was even higher than control cells. 
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The substantially impeded movement of combination-treated cells could be related to the large 
difference in speed observed between the CB and LE. LE speed remains high, continuing to protrude 
and retract, but the cell is incompetent to degrade matrix and/or make anchor points, due to NEDD9 
deficiency. Meanwhile, the cell rear cannot efficiently contract due to inhibition of ROCK/RhoA, leaving 
the CB more immobile. This combination therefore results in a severe gap between a stagnant, 
immotile CB along with a quickly protruding/retracting, yet functionally impaired LE. These results 
support the notion that simultaneous inhibition of both the NEDD9/AURKA and ROCK/RhoA pathways 
could be an efficient anti-migratory/metastasis treatment option. These conclusions were further 
supported by our findings in an in vivo breast cancer xenograft mouse model, demonstrating a 
significant reduction in the number of circulating tumor cells and pulmonary metastases of mice that 
received combination treatment. These findings are also in agreement with previously published 
reports of NEDD9 depletion showing a decrease in the invasion and dissemination of diverse cancer 
types in vivo (1, 2).  
In conclusion, while NEDD9-deficient cells may have many hallmarks of amoeboid phenotype, 
we have shown that amoeboid movement appears defective in some respects such as decreased cell 
contractility. Nonetheless, depletion of RhoA or addition of ROCK inhibitor to NEDD9-deficient cells 
provided additional benefit in further hindrance of cell invasion/metastasis. Through concurrent 
targeting of these pathways, this approach merits further evaluation as a clinical option to augment 
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Fig. 1. TNBC cell morphology changes upon NEDD9 and ROCK inhibition 
(A) Western blot analysis of NEDD9 expression in MDA-MB-231, HCC1143, and Hs578T treated with 
multiple siRNAs. (B) Brightfield images of MDA-MB-231, HCC1143, and Hs578T cells treated with 
siCon or siNEDD9 in 3D collagen I and (C) cell elongation quantified as cell length/width (40 
cells/group). (D) Brightfield images of BT549, HCC1395, and SUM159 cells expressing siCon, 
siNEDD9, or CA-RhoA, (E) cell elongation quantified as cell length/width (100 cells/group), and (F) 
western blots of NEDD9 knockdown and CA-RhoA expression. (G) Brightfield images of TNBC cells, 
vehicle or Y-27632 treatment and (H) cell elongation quantified as cell length/width (40 cells/group). 
ns, not significant; *p<0.05, student’s t-test vs control. 
Fig. 2. NEDD9 depletion increases phosphorylation of MLC2 and decreases phosphorylation 
of FAK and paxillin  
(A) MDA-MB-231 siCon and siNEDD9 cells in collagen I stained for pMLC2, actin, and Hoechst DNA 
dye. Scale bar, 20 µm. (B) Box and whisker plot of pMLC2 relative fluorescence intensity (RFI), n = 3, 
20-30 cells/group. Intensity was normalized to the cell area. (C) Western blot and (D) quantification of 
MLC2 phosphorylation, n = 3. (E) Collagen gel contraction assay of MDA-MB-231 CRISPR 
sgCon/sgNEDD9 cells over 24 hours and (F) quantification of collagen gel area, n = 3. (G) MDA-MB-
231 siCon and siNEDD9 cells in collagen I stained for pFAKY397 or pPaxillinY31 and Hoechst DNA dye. 
Scale bar, 20 µm. (H) Box and whisker plot of pFAKY397 fluorescence and (I) pPaxillinY31 fluorescence, 
n = 3, at least 20 cells/group. (J) Quantification of # of focal adhesions per cell, n = 3, at least 20 
cells/group. (K) Western blot and quantification of (L) FAK and (M) paxillin phosphorylation. n = 3. 
*p<0.05, student’s t-test vs control. 
Fig. 3. NEDD9 regulates AURKA-driven phosphorylation of CTTN and stability of actin 
filaments 
(A) Radioactive in vitro kinase assay of recombinant AURKA and full length WT CTTN proteins using 
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radiolabeled P32-ATP, n = 3. WB shows total protein (top and middle) while autoradiograph shows 
P32-phosphorylated protein (bottom). (B) Radioactive in vitro kinase assay of recombinant AURKA 
and N-term (1-350 aa) and C-term (350-546 aa) CTTN proteins using radiolabeled P32-ATP, n = 3. 
WB shows total protein (top and middle) while autoradiograph shows P32-phosphorylated protein 
(bottom, 24 hour exposure). (C) Pyrene-actin polymerization assay of AURKA and CTTN, n = 4. 
Curves were fit with Boltzmann sigmoidal analysis, *p<0.05. (D) Kymographs of cell membrane of 
MDA-MB-231 cells treated with Vehicle or MLN8237 and quantifications of (E) protrusion velocity and 
(F) maximum membrane extension. n.d., not detected. 
Fig. 4. NEDD9 drives Rac1 activity through interaction with GEF VAV2 
(A) Western blot of active-Rac1 pulldown (PD) from MDA-MB-231 siCon/siNEDD9 cells in 3D Matrigel 
using GST-PBD conjugated beads. Lane 1: GST-empty beads control. WCL, whole cell lysate. (B) 
Quantification of Rac1 activity in 3D collagen and Matrigel (active/total Rac1) by WB. (C) Quantification 
of RhoA activity in 3D collagen and Matrigel by G-LISA. (D) Co-immunoprecipitation of HA-VAV2 and 
RFP-NEDD9 through IP of each protein. IgG, mouse IgG control. (E) Western blot of active-Rac1 
pulldown from MDA-MB-231 siCon/siVAV2 cells and (F) quantification of Rac1 activity. (G) Western 
blot of active-Rac1 pulldown from GFP-NEDD9 overexpressing MDA-MB-231 siCon/siVAV2 cells. 
Lane 1: GST-empty beads control. WCL, whole cell lysate. Exog, exogenous. Endog, endogenous. 
For all experiments: n = 3, *p<0.05, student’s t-test vs control. 
Fig. 5. Simultaneous targeting of NEDD9 and ROCK/RhoA hinders breast cancer cell 
motility/invasion in vitro 
(A) Brightfield outlined cell morphology images (~12 hours), (B) individual cell tracking movement plots 
toward FBS chemoattractant (left), box and whisker plots of (C) cell body (CB) and leading edge (LE) 
speed, (D) cell body directionality, and (E) cell elongation of MDA-MB-231 cells with siCon/siNEDD9 
+ Vehicle/Y-27632 treatment in 3D collagen Ibidi chemotactic invasion movies. Scale bar, 20 µm. n = 
3, 30-40 cells per group. ns, not significant; *p<0.05, one-way ANOVA. (F) GFP immunofluorescence 
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images and box and whisker plots of (G) cell body speed and (H) cell body directionality of MDA-MB-
231 pGIPZ-GFP shControl and shNEDD9 cells after 24 hours being densely seeded in a 3D Matrigel 
sandwich assay. Scale bar: 20 µm. n = 3, at least 60 cells per group. *p<0.05, student’s t-test vs 
control. (I) 3D projection boxes and (J) collective invasion quantification of the amount of MDA-MB-
231 pGIPZ-GFP shControl/shNEDD9 cells reaching 100 µm invasion distance after 72 hours being 
densely seeded in a 3D Matrigel sandwich assay. *p<0.05, student’s t-test vs control.  (K) Western 
blot of shNEDD9 knockdown in collective invasion assay. 
Fig. 6. Simultaneous targeting of NEDD9 and ROCK hinders breast cancer cell invasion and 
metastasis in vivo 
(A) MDA-MB-231-luc2 TZ RFP-shCon and RFP-shNEDD9 cells injected into the mammary fat pad of 
NSG mice were grown for ~3.5 weeks before starting treatment (time 0) for 3 weeks with 10 mg/kg Y-
27632 and shRNA induction. (B) Weekly images of tumor cells in vivo via bioluminescence signal 
which was (C) quantified at the primary tumor site. (D) Western blot and (E) quantification of NEDD9 
knockdown in final primary tumors. (F) Quantification of number of RFP-positive circulating tumor cells 
in mouse blood by FACS analysis. (G) Quantification of number of visible metastases per area of lung 
tissue. (H) Proposed schematic of mesenchymal and amoeboid pathways in breast cancer. n = 5 










































Fig. S1. NEDD9 depletion causes a switch to amoeboid morphology 
(A) Brightfield images of outlined siControl and SMARTpool siNEDD9 MDA-MB-231, HCC1143, and 
Hs578T cells in 2D and (B) cell elongation quantified as cell length/width (at least 60-70 cells/group). 
(C) Scanning electron microscopy images of bovine skin collagen I and Matrigel matrices. (D) Box 
and whisker plot of collagen pore cross section area (n = 40 pores). (E) Western blot of NEDD9 
knockdown with two CRISPR sgRNAs in MDA-MB-231 cells. (F) Quantification of MDA-MB-231 cell 
elongation with SMARTpool CRISPR sgNEDD9 knockdown (at least 120 cells/group). (G) MDA-MB-
231 siCon and siNEDD9 cells in Matrigel stained for pFAKY397 and DNA dye. (H) Box and whisker plot 
of pFAKY397 fluorescence, (I) quantification of # of focal adhesions per cell and (J) box and whisker 
plot of pMLC2 fluorescence intensity in Matrigel, n = 3, at least 30 cells/group. Scale bars, 20 μm. 




Fig. S2. NEDD9 depletion decreases phosphorylation of focal adhesion proteins in other BC 
cell lines 
(A) Western blot and quantification of (B) pFAKY397 and (C) pPaxillinY31 phosphorylation in Hs578T 
breast cancer cells. (D) Western blot and quantification of (E) pFAKY397 and (F) pPaxillinY31 










Fig. S3. NEDD9 depletion affects vinculin-containing focal adhesion dynamics 
(A) MDA-MB-231 sgCon and sgNEDD9 cells +/- Y-27632 treatment stained for vinculin with 
additional stains for phospho-p130casY234, actin, and Hoechst DNA dye. Scale bars, 20 μm. (B) 
Quantification of vinculin-positive focal adhesion length. (C) Quantification of # of vinculin-positive 
focal adhesions. *p<0.05, one-way ANOVA. (D) Schematic of focal adhesion maturation under 
NEDD9 knockdown. NA, nascent adhesion; FA, focal adhesion; fbFA, fibrillar focal adhesion. 
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Fig. S4. NEDD9 depletion affects talin-containing focal adhesion dynamics 
(A) MDA-MB-231 sgCon and sgNEDD9 cells +/- Y-27632 treatment stained for talin with additional 
stains for phospho-p130casY234, actin, and Hoechst DNA dye. Scale bars, 20 μm. (B) Quantification 
of talin-positive focal adhesion length. (C) Quantification of # of talin-positive focal adhesions. 




Fig. S5. AURKA phosphorylates CTTN in breast cancer cells 
Immunoprecipation (IP) of CTTN with mouse monoclonal antibody (4F11) from MDA-MB-231 cells 
overexpressing RFP-AURKA and treated overnight with Vehicle or 100 nM AURKA-inhibitor 
MLN8237. Western blotted with pan-phospho-serine antibody. IgG, mouse IgG control. WCL, whole 














Fig. S6. NEDD9 depletion decreases Rac1 activity in other breast cancer cell lines 
(A) Western blot of active-Rac1 pulldown from exogenous GST-tagged constitutively active or 
dominant negative Rac1-expressing MDA-MB-231 cells to show the activity specificity of GST-PBD 
beads. (B) Quantifications of Rac1 activity in 3D collagen and Matrigel (active/total Rac1) in 
pulldowns from Hs578T and (C) HCC1143 cells, n = 3, *p<0.05, student’s t-test vs control. (D) 
Quantification of Rac1 activity in 3D collagen and Matrigel by G-LISA, *p<0.05, student’s t-test vs 
control. (E) Endogenous VAV2 and (F) DEF6 IPs from MDA-MB-231 cells via NEDD9 pulldown, n = 
3. IgG, mouse IgG control. (G) Western blot of active-Rac1 pulldown from MDA-MB-231 
siCon/siNEDD9 cells + Vehicle/EHop-016 with (H) quantification of Rac1 activity (active/total Rac1). 






Fig. S7. Depletion of NEDD9 via CRISPR-Cas9 system and overexpression of CA-RhoA 
decreases cell invasion and increases round amoeboid phenotype 
(A) Brightfield outlined cell morphology images (~12 hours), (B) individual cell tracking movement 
plots toward FBS chemoattractant (left), and box and whisker plots of (C) cell body speed and (D) 
cell body directionality of MDA-MB-231 sgCon/sgNEDD9 cells in 3D collagen Ibidi chemotactic 
invasion movies, 30-40 cells/group. (E) Western blot of exogenous CA-RhoA overexpression in 
MDA-MB-231 cells. (F) Brightfield outlined cell morphology images (~12 hours), (G) box and whisker 
plot of cell elongation, (H) individual cell tracking movement plots toward FBS chemoattractant (left), 
and box and whisker plots of (I) cell body (CB) speed and (J) cell body directionality of MDA-MB-231 
control and CA-RhoA overexpressing cells in 3D collagen Ibidi chemotactic invasion movies, 30-40 




Fig. S8. Simultaneous inhibition of mesenchymal and amoeboid pathways through NEDD9 
and RhoA knockdown hinders cell invasion in vitro 
(A) Western blot of NEDD9 and RhoA knockdown in MDA-MB-231 cells. (B) Brightfield outlined cell 
morphology images (~12 hours), (C) box and whisker plot of cell elongation, (D) individual cell 
tracking movement plots toward FBS chemoattractant (left), and box and whisker plots of (E) cell 
body (CB) speed and (F) cell body directionality of MDA-MB-231 cells with siCon, siNEDD9, or 
siRhoA in 3D collagen Ibidi chemotactic invasion movies, n = 3, 30-40 cells/group. Scale bars, 20 




Fig. S9. Depletion of NEDD9 hinders invasion of other breast cancer cell lines in vitro 
(A) Western blot of SMARTpool siNEDD9 treatment in Hs578T and (B) HCC1143 cells. (C-H) 
Individual cell tracking movement plots toward FBS chemoattractant (C-D, left) and box and whisker 
plots of cell body speed and cell body directionality of (C, E-F) Hs578T and (D, G-H) HCC1143 
siCon/siNEDD9 cells in 3D collagen Ibidi chemotactic invasion movies, n = 3, 30-40 cells/group. 









Fig. S10. AURKA inhibition hinders breast cancer cell invasion 
(A) Quantification of Euclidean distance and (B) total distance invaded by MDA-MB-231 
siCon/siNEDD9 cells (+/- MLN8237 and Y-27632 treatment) in 3D collagen Ibidi chemotactic 
individual cell invasion assays, at least 60 cells/group. *p<0.05, one-way ANOVA. (C) 3D projection 
boxes and (D) collective invasion quantification of the amount of MDA-MB-231 pGIPZ-GFP 
shControl/shNEDD9 cells (+/- MLN8237 and Y-27632 treatment) reaching 100 μm invasion distance 
after 72 hours being densely seeded in a 3D matrigel sandwich assay. n = 3, *p<0.05, one-way 






Table S1. Co-immunoprecipitation results of NEDD9 with multiple GEF proteins 
Results from co-immunoprecipitations of exogenous NEDD9 and multiple different al Rac1 GEFs in 
293T cells. Multiple GEFs were found to pull down with NEDD9 protein, but only VAV2 was found to 
















Video S1. Ibidi chemotactic invasion of MDA-MB-231 cells with NEDD9 depletion and ROCK 
inhibition 
Movie of individual MDA-MB-231 siCon/siNEDD9 cells treated with Vehicle or Y-27632 in 3D collagen 
manually tracked over the course of 23 hours. A serum chemoattractant-containing reservoir was 
present on the left side of the frame. 
Video S2. Ibidi chemotactic invasion of MDA-MB-231 cells with CRISPR sgNEDD9 depletion 
Movie of individual MDA-MB-231 sgCon/sgNEDD9 cells in 3D collagen manually tracked over the 
course of 23 hours. A serum chemoattractant-containing reservoir was present on the left side of the 
frame. 
Video S3. Ibidi chemotactic invasion of MDA-MB-231 cells with CA-RhoA overexpression 
Movie of individual CA-RhoA expressing MDA-MB-231 cells in 3D collagen manually tracked over the 
course of 23 hours. A serum chemoattractant-containing reservoir was present on the left side of the 
frame. 
Video S4. Ibidi chemotactic invasion of MDA-MB-231 cells with NEDD9 and RhoA depletion 
Movie of individual MDA-MB-231 siCon/siNEDD9/siRHOA cells in 3D collagen manually tracked over 
the course of 23 hours. A serum chemoattractant-containing reservoir was present on the left side of 
the frame. 
Video S5. Ibidi chemotactic invasion of Hs578T cells with NEDD9 depletion 
Movie of individual Hs578T siCon/siNEDD9 cells in 3D collagen manually tracked over the course of 
23 hours. A serum chemoattractant-containing reservoir was present on the left side of the frame. 
Video S6. Ibidi chemotactic invasion of HCC1143 cells with NEDD9 depletion 
Movie of individual HCC1143 siCon/siNEDD9 cells in 3D collagen manually tracked over the course 
of 46 hours. A serum chemoattractant-containing reservoir was present on the left side of the frame. 
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Video S7. Ibidi chemotactic invasion of MDA-MB-231 cells with AURKA and ROCK inhibition 
Movie of individual MDA-MB-231 cells treated with MLN8237 or Y-27632 in 3D collagen manually 
tracked over the course of 23 hours. A serum chemoattractant-containing reservoir was present on 
the left side of the frame. 
Video S8. Collective invasion of MDA-MB-231 cells with NEDD9 depletion 
Movie of collective invasion of densely seeded MDA-MB-231 pGIPZ-GFP shCon/shNEDD9 cells in 




















Supplemental Materials and Methods 
RNAs and plasmids 
pGIPZ and pTRIPZ-shControl/NEDD9 shRNAs (ThermoFisher Scientific), Control siRNA 
(Bioneer and Origene), NEDD9 siRNA (2-siRNA SMARTpool  of 1: Dharmacon #D-019466-22 and 2: 
#D-019466-23), RhoA siRNA (3-siRNA SMARTpool: Origene #SR300278A, SR300278B, and 
SR300278C), and VAV2 siRNA (3-siRNA SMARTpool: Origene #SR305062A, SR305062B, and 
SR305062C) were used based on manufacturers’ recommendations. lentiCRISPRv2 plasmid was a 
gift from Feng Zhang (Addgene plasmid #52961) (1). NEDD9 sgRNA (sequence #1: 
GTACCCATCCAGATACCAAA, #2: TGTGGAGGATGAGTTCCGGG) was designed using Broad 
Institute sgRNA Designer online tool and subcloned into lentiCRISPRv2 as described (2). pEGFP-C3-
Rac1-T17N dominant negative (DN), pEYFP-C1-Rac1-Q61L constitutively active (CA), and pEGFP-
C3-RhoA-Q63L (CA) plasmids were a gift from Dr. Michael Schaller (West Virginia University). pGST-
parallel2-CTTN-WT, pGST-parallel2-CTTN-Nterm-1-350, and pGST-parallel2-CTTN-Cterm-350-546 
were a gift from Dr. Scott Weed (West Virginia University). pDEST/LifeAct-mCherry-N1 was a gift from 
Robin Shaw (Addgene plasmid #40908) (3). pGEX-6P-1 (Amersham) and pGEXTK-Pak1 70-117 (gift 
from Jonathan Chernoff, Addgene plasmid #12217) plasmids were used to produce GST-control and 
GST-Pak1 binding domain (PBD) proteins respectively for pulldowns. pcDNA3-FLAG-NEDD9 and 
pcDNA3.1-mRFP-NEDD9 were previously reported (4). pC.HA Vav2 was a gift from Joan Brugge 
(Addgene plasmid # 14554) (5). YF-Tiam1 was a gift from Tobias Meyer (Addgene plasmid # 20154) 
(6). ARHGEF2 (GE Healthcare), DEF6 (PlasmID), ARHGEF4 (PlasmID), and Dbl (gift from Dr. Xosé 
Bustelo, University of Salamanca-CSIC) were subcloned into pcDNA3.1-6HA vector. pCEV32F3-
ECT2 plasmid was a gift from Dr. Toru Miki (Nagaoka University of Technology). pCMV5-HA3-GEF-
H1 plasmid was a gift from Dr. Celine de Mardirossian (The Scripps Research Institute). The indicated 
above plasmids or RNAs were introduced via nucleofection (Amaxa) according to manufacturer’s 
recommendation or virus infection (293T packaging cells, LifeTechnologies) as previously described 
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(7). 
Matrix pore size analysis  
Confocal reflection microscopy: The lattice of 1.5mg/ml 3D bovine skin collagen I (Advanced 
BioMatrix) was imaged using confocal reflection microscopy (Zeiss-LSM510, 63X objective with 2µm 
steps) as previously described (8). The images were rendered as a 3D projection using ImageJ 
software (NIH) (9) and pore size was quantified by manually outlining visible holes in the lattice to 
calculate cross sections. 
Scanning electron microscopy: 1.5mg/ml collagen and 4mg/ml Matrigel (Corning) were fixed 
with glutaraldehyde and dehydrated with increasing ethanol. Matrices were then dried and sputtered 
for 120 seconds with a Denton Desk V Sputter. Samples were imaged using a Hitachi S-4700F 
scanning electron microscope. 
Western blotting 
Samples were prepared in Laemmli buffer, resolved in Bolt 4-12% Bis-Tris/Novex acrylamide 
gel (LifeTechnologies), transferred onto 0.45µm PVDF membrane (Millipore), and blocked with 5% 
milk or bovine serum albumin in PBS or TBS with 0.05% Tween-20 (Fisher). Antibodies used included: 
NEDD9 (2G9, (10)), α-tubulin (Sigma), pMLC2Thr18/Ser19 (Cell Signaling), MLC2 (Cell Signaling), 
pPaxillinY31 (Biosource), paxillin (Calbiochem), pFAKY397 (Calbiochem), FAK (Calbiochem), AURKA 
(AurA-N, custom (4)), CTTN (4F11, gift from Dr. Scott Weed, West Virginia University), CTTN (H-191, 
Santa Cruz), pan-phospho-serine (Zymed), Rac1 (Cytoskeleton), RhoA (Cell Signaling), GAPDH 
(Millipore), VAV2 (Santa Cruz), DEF6 (Santa Cruz), HA-tag (Cell Signaling), Flag-tag (Cell Signaling), 
and HRP-conjugated anti-rabbit/anti-mouse (Jackson ImmunoResearch). Protein bands were 
detected with HyGLO chemiluminescent HRP detection reagent (Denville), imaged (Syngene G:Box), 
and quantified using GeneTools 4.01 software from Syngene as previously described (7). 
Immunofluorescence 
In addition to antibodies already described for WB, additional antibodies/stains used for IF 
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included Rhodamine-Phalloidin (Cytoskeleton), Vinculin (Santa Cruz), Talin (Santa Cruz), Tensin (gift 
from Dr. Michael Schaller, West Virginia University), p-p130casY234 (Open Biosystems), Alexa Fluor 
647-phalloidin (Invitrogen), anti-rabbit or anti-mouse Alexa Fluor 488/555/647-IgG (Jackson 
ImmunoResearch), and Hoechst-33342 DNA dye (LifeTechnologies). Coverslips were mounted using 
ProLong anti-fade reagent (LifeTechnologies) and imaged using a Zeiss-LSM510 microscope and 
63X objective and rendered as 3D projections using ImageJ software. Relative fluorescence intensity 
(RFI) was measured as the mean gray value per cell area in ImageJ. Focal adhesion length was 
measured and the number of adhesions was counted per cell and normalized to the total cell area. 
Immunoprecipitation and western blot of cortactin phosphorylation in cells 
 AURKA overexpression was induced with doxycycline overnight in MDA-MB-231  pLUTZ-
mRFP-AURKA cells and then treated for 24 hours with 100nM MLN8237. Cells were lysed with PTY 
lysis buffer and processed as previously described (10). Lysates were precleared with protein-A/G-
sepharose (GE Healthcare) for 1 hour at 4°C. Mouse IgG control or anti-CTTN (4F11) antibodies were 
added to precleared lysates overnight rotating at 4°C. Protein-A/G-sepharose beads preblocked with 
bovine serum albumin were added to the rotating tubes for 2 hours. Beads were allowed to settle for 
15 minutes on ice, then washed three times with PTY buffer. Beads were resuspended in Laemmli 
buffer and boiled at 100°C to elute proteins for gel electrophoresis and western blotting. Pan-phospho-
serine antibody (Zymed) was used to stain for cortactin phosphorylation on the WB and total cortactin 
was stained with another cortactin specific antibody (H-191, Santa Cruz).  
Quantification of cell invasion movies 
Cell elongation was measured as a function of cell length to cell width at the midpoint of the 
movies to give cells adequate time to adapt to their surroundings and capture their morphology during 
invasion. Cell body and leading edge speeds were calculated by manually tracking physical movement 
of either the main cell body or the protruding/retracting leading edge using MTrackJ plugin for ImageJ 
(11). Cell body directionality was measured from the tracking data as a function of Euclidean distance 
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from the initial starting point over the total distance traveled. Individual cell movement tracking plots 
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CHAPTER 3: SUMMARY 
 
The work detailed in this dissertation uncovers significant insights into the mechanisms 
and therapeutic viability of inhibiting NEDD9-driven mesenchymal migration and invasion in 
combination with amoeboid pathway targeting. Triple negative breast cancer has remained an 
extremely prevalent and deadly cancer with minimal treatment options available for patients, 
especially for those patients who are metastatic. Metastasis from the primary tumor site is the 
most life threatening aspect of TNBC, making the inhibition of cancer cell movement an ideal 
treatment strategy in order to stop its spread to distant organs. 
In this project, we report a novel relationship between NEDD9 and the Rac1 GEF VAV2 
in breast cancer, where NEDD9 expression contributes to Rac1 activation in a VAV2-dependent 
manner. This VAV2-Rac1 signaling cascade in combination with another NEDD9-driven 
signaling network through AURKA-HDAC6-CTTN, both of which contribute to actin 
polymerization dynamics and subsequent lamellipodia/invadopodia formation, makes NEDD9 
a prime therapeutic target to downregulate mesenchymal movement. In addition, we report the 
novel finding that NEDD9 inhibition by itself seems to hinder aspects of both mesenchymal and 
amoeboid migration phenotypes. These cells lose many mesenchymal characteristics and gain 
an amoeboid-like phenotype – becoming more rounded, losing large mature focal adhesions 
and gaining nascent adhesions, and increasing phosphorylation of myosin light chain. 
Nevertheless, while appearing amoeboid, they are functionally reduced by not translating these 
amoeboid features into increased cell contractility in collagen gel assays. This may be linked to 
some disruption between the myosin motors and actin filaments or a deficiency in adhesion 
disassembly – future work on this topic will be interesting to pursue. 
Furthermore, we report that inhibition of NEDD9 causes a severe decrease in breast 
cancer cell invasion, pulmonary metastases, and circulating tumor cells in the mouse blood 
stream, which can be exacerbated even further through simultaneous treatment with ROCK-
87  
targeting compounds. Similar results in invasion inhibition were obtained through targeting of 
AURKA and RhoA proteins. Combination of such treatments, which impede critical components 
of both mesenchymal and amoeboid pathways, yields cells with very long morphology that have 
thin needle-like leading edge protrusions and lagging cell rears, possibly due to reduced MMP 
activation in the front and a deficiency in rear cell contractility to bring the cell forward. These 
results highlight the potential for NEDD9 as a promising new therapeutic target, and 
additionally, highlights the dual pathway inhibition strategy as a viable and encouraging 
approach which merits further study for its possible application into clinical trials for human 
breast cancer patients. 
 
